Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Medical Instruments and Supplies

ResMed Inc. develops, manufactures, and markets medical equipment for the treatment of sleep disordered breathing. The Company sells diagnostic and treatment devices in various countries through its subsidiaries and independent distributors.
Website: resmed.com



Growth: Good revenue growth rate 11.0%, there is slowdown compared to average historical growth rates 13.0%. The revenue growth dynamics is moderately stable Site traffic for the last 3 months showed a change of -4.6%

Profitability: LTM EBITDA margin is positive, +37.5%. On average the margin is improving unsteadily. In the last quarter the company beat the estimated EPS, +5.7%. The company was ahead of estimated EPS in 60% of quarters (showing a gain of +$0.01 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.9%. Free cash flow yield 2.4% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 89.7% higher than minimum and 13.0% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 4.0x by EV / Sales multiple , the company can be 41.8% overvalued

Insiders: For the last 3 months insiders sold company shares on $5.9 mln (-0.016% of cap.)

Key Financials (Download financials)

Ticker: RMD
Share price, USD:  (0.0%)255.47
year average price 251.55  


year start price 236.94 2025-02-08

min close price 204.54 2025-04-08

max close price 293.73 2025-08-22

current price 255.47 2026-02-07
Common stocks: 145 842 000

Dividend Yield:  0.9%
FCF Yield LTM: 2.4%
EV / LTM EBITDA: 18.1x
EV / EBITDA annualized: 16.9x
Last revenue growth (y/y):  +11.0%
Last growth of EBITDA (y/y):  +16.8%
Historical revenue growth:  +13.0%
Historical growth of EBITDA:  +19.6%
EV / Sales: 6.8x
Margin (EBITDA LTM / Revenue): 37.5%
Fundamental value created in LTM:
Market Cap ($m): 37 258
Net Debt ($m): -569
EV (Enterprise Value): 36 689
Price to Book: 6.1x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-02-01seekingalpha.com

ResMed: Facing A Potentially Dream-Disrupting Dose - Strong Sell

2026-01-29seekingalpha.com

ResMed Inc. (RMD) Q2 2026 Earnings Call Transcript

2026-01-29zacks.com

ResMed (RMD) Reports Q2 Earnings: What Key Metrics Have to Say

2026-01-29zacks.com

Are Medical Stocks Lagging ResMed (RMD) This Year?

2026-01-28zacks.com

Will ResMed (RMD) Beat Estimates Again in Its Next Earnings Report?

2026-01-22zacks.com

ResMed (RMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

2026-01-13zacks.com

Why ResMed (RMD) is a Top Momentum Stock for the Long-Term

2025-12-30zacks.com

Is ResMed (RMD) a Solid Growth Stock? 3 Reasons to Think "Yes"

2025-12-03zacks.com

Should You Continue to Hold RMD Stock in Your Portfolio?

2025-11-24forbes.com

IDEXX Laboratories Vs ResMed: Which Stock Could Rally?
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q2
date 2025-09-30 2025-06-30 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-06-30
symbol RMD RMD RMD RMD RMD RMD RMD RMD RMD RMD RMD RMD RMD
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 943 819 943 819 943 819 943 819 943 819 943 819 943 819 943 819 943 819 943 819 943 819 943 819 943 819
fillingDate 2025-10-31 2024-10-25 2024-04-26 2024-01-25 2023-10-27 2023-04-28 2023-01-27 2022-10-28
acceptedDate 2025-10-30 20:01:49 2025-08-07 20:44:48 2024-10-24 19:37:22 2024-08-08 20:09:34 2024-04-25 19:18:46 2024-01-24 19:50:30 2023-10-26 19:38:03 2023-08-10 20:15:16 2023-04-27 19:15:37 2023-01-26 18:09:53 2022-10-27 18:26:57 2022-08-11 21:09:45 2021-08-16 21:43:33
calendarYear 2026 2025 2024 2024 2024 2023 2023 2023
period Q1 FY Q1 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY FY
revenue 1 336M 5 146M 1 225M 4 685M 1 197M 1 163M 963M 4 223M 1 117M 1 034M 950M 3 578M 3 197M
costOfRevenue 515M 2 091M 507M 2 030M 515M 516M 363M 1 867M 499M 454M 409M 1 554M 1 358M
grossProfit 821M 3 055M 717M 2 655M 682M 647M 600M 2 356M 618M 580M 541M 2 024M 1 839M
grossProfitRatio 0.615 0.586 0.569 0.556 0.623 0.553 0.561 0.569
researchAndDevelopmentExpenses 87M 331M 80M 308M 77M 74M 76M 288M 76M 70M 63M 254M 225M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 259M 991M 239M 917M 230M 222M 223M 874M 228M 212M 194M 739M 670M
otherExpenses 28M 47M 11M 111M -2M -686 000 12M 62M 12M 10M 8M 31M 40M
operatingExpenses 374M 1 370M 330M 1 335M 307M 308M 311M 1 224M 317M 291M 265M 1 024M 935M
costAndExpenses 889M 3 461M 837M 3 365M 822M 823M 674M 3 091M 816M 745M 675M 2 578M 2 293M
interestIncome 0 0 0 0 0 0 18M 0 0 0 0 0 362 000
interestExpense 9M 13M 0 46M -11M -14M -15M 47M -15M -10M -7M 22M 24M
depreciationAndAmortization 48M 236M 54M 216M 55M 53M 53M 197M 46M 62M 23M 194M 192M
ebitda 503M 1 913M 443M 1 534M 429M 457M 289M 1 359M 347M 343M 299M 1 177M 1 104M
ebitdaratio 0.377 0.362 0.359 0.393 0.3 0.311 0.331 0.314
operatingIncome 447M 1 685M 387M 1 320M 375M 275M 289M 1 132M 301M 280M 276M 1 000M 904M
operatingIncomeRatio 0.334 0.316 0.313 0.237 0.3 0.269 0.271 0.29
totalOtherIncomeExpensesNet 256 000 -8M -4M -55M 837 000 -66M -17M -30M -11M -7M -14M -40M -20M
incomeBeforeTax 447M 1 678M 383M 1 265M 375M 259M 272M 1 102M 289M 274M 262M 960M 884M
incomeBeforeTaxRatio 0.335 0.313 0.314 0.223 0.283 0.259 0.265 0.275
incomeTaxExpense 98M 277M 72M 244M 75M 51M 53M 204M 57M 49M 51M 181M 409M
netIncome 349M 1 401M 311M 1 021M 300M 209M 219M 898M 233M 225M 210M 779M 475M
netIncomeRatio 0.261 0.254 0.251 0.18 0.228 0.208 0.218 0.221
eps 2.38 9.55 2.12 6.94 2.04 1.42 1.49 6.12 1.58 1.53 1.44 5.34 3.27
epsdiluted 2.37 2.11 2.04 1.42 1.49 1.58 1.53 1.43
weightedAverageShsOut 146M 147M 147M 147M 147M 147M 147M 147M 147M 147M 146M 146M 145M
weightedAverageShsOutDil 147M 147M 148M 148M 147M 148M 147M 147M 147M 147M 147M 147M 146M
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link
filingDate 2025-08-08 2024-08-09 2023-08-11 2022-08-12 2021-08-17
fiscalYear 2025 2024 2023 2022 2021
netInterestIncome -13M -46M -47M -22M -24M
ebit 1 678M 1 311M 1 162M 983M 912M
nonOperatingIncomeExcludingInterest 10M 9M -30M 17M -9M
netIncomeFromContinuingOperations 1 401M 1 021M 898M 779M 475M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome 1 401M 1 021M 898M 779M 475M
epsDiluted 9.51 6.92 6.09 5.3 3.24

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q2
date 2025-09-30 2025-06-30 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-06-30
symbol RMD RMD RMD RMD RMD RMD RMD RMD RMD RMD RMD RMD RMD
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 943 819 943 819 943 819 943 819 943 819 943 819 943 819 943 819 943 819 943 819 943 819 943 819 943 819
fillingDate 2025-10-31 2024-10-25 2024-04-26 2024-01-25 2023-10-27 2023-04-28 2023-01-27 2022-10-28
acceptedDate 2025-10-30 20:01:49 2025-08-07 20:44:48 2024-10-24 19:37:22 2024-08-08 20:09:34 2024-04-25 19:18:46 2024-01-24 19:50:30 2023-10-26 19:38:03 2023-08-10 20:15:16 2023-04-27 19:15:37 2023-01-26 18:09:53 2022-10-27 18:26:57 2022-08-11 21:09:45 2021-08-16 21:43:33
calendarYear 2026 2025 2024 2024 2024 2023 2023 2023
period Q1 FY Q1 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY FY
cashAndCashEquivalents 1 384M 1 209M 426M 238M 238M 210M 209M 228M 228M 253M 207M 274M 295M
shortTermInvestments 0 0 0 0 22M 8M 12M 0 0 0 0 0 0
cashAndShortTermInvestments 1 384M 1 209M 426M 238M 238M 210M 209M 228M 228M 253M 207M 274M 295M
netReceivables 958M 991M 811M 837M 817M 730M 692M 705M 686M 672M 620M 576M 614M
inventory 946M 928M 918M 822M 829M 933M 958M 998M 1 011M 989M 865M 744M 457M
otherCurrentAssets 338M 164M 486M 180M 467M 180M 445M 180M 412M 147M 341M 131M 0
totalCurrentAssets 3 626M 3 506M 2 641M 2 358M 2 351M 2 378M 2 305M 2 368M 2 338M 2 325M 2 034M 1 931M 1 575M
propertyPlantEquipmentNet 726M 718M 717M 699M 687M 705M 657M 666M 656M 651M 613M 630M 592M
goodwill 3 044M 3 047M 2 886M 2 842M 2 836M 2 862M 2 812M 2 770M 2 784M 2 767M 1 939M 1 936M 1 928M
intangibleAssets 447M 465M 479M 486M 501M 528M 563M 552M 570M 587M 338M 346M 393M
goodwillAndIntangibleAssets 3 491M 3 512M 3 365M 3 328M 3 337M 3 390M 3 375M 3 323M 3 353M 3 354M 2 277M 2 282M 2 320M
longTermInvestments 165M 85M 0 170M 175M 160M -265M 157M 0 -346M 0 67M 75M
taxAssets 276M 253M 221M 204M 162M 156M 403M 133M 96M 346M 81M 80M 80M
otherNonCurrentAssets 25M 101M 279M 114M 102M 116M 265M 106M 271M 346M 173M 105M 85M
totalNonCurrentAssets 4 683M 4 669M 4 581M 4 515M 4 463M 4 527M 4 436M 4 384M 4 376M 4 351M 3 144M 3 164M 3 153M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 8 308M 8 174M 7 222M 6 872M 6 815M 6 905M 6 741M 6 752M 6 714M 6 676M 5 178M 5 096M 4 728M
accountPayables 267M 278M 249M 238M 177M 202M 177M 151M 162M 196M 181M 159M 138M
shortTermDebt 290M 10M 38M 10M 34M 34M 32M 10M 33M 32M 31M 10M 12M
taxPayables 135M 0 94M 108M 55M 47M 67M 72M 78M 58M 48M 45M 308M
deferredRevenue 168M 166M 157M 153M 151M 149M 147M 138M 141M 134M 108M 109M 110M
otherCurrentLiabilities 396M 3M 366M 5M 411M 379M 415M 10M 426M 370M 372M 2M 0
totalCurrentLiabilities 1 256M 1 019M 904M 911M 773M 764M 771M 759M 762M 733M 693M 689M 912M
longTermDebt 556M 658M 812M 697M 997M 1 357M 1 464M 1 431M 1 691M 1 907M 900M 765M 643M
deferredRevenueNonCurrent 159M 157M 144M 137M 132M 127M 121M 119M 109M 103M 98M 95M 91M
deferredTaxLiabilitiesNonCurrent 78M 78M 84M 79M 87M 89M 88M 91M 113M 108M 12M 10M 11M
otherNonCurrentLiabilities 138M 142M 83M 42M 196M 85M 46M 105M 107M 88M 731M 55M 70M
totalNonCurrentLiabilities 932M 1 187M 1 123M 1 098M 1 412M 1 659M 1 720M 1 863M 2 020M 2 205M 1 052M 1 046M 931M
otherLiabilities 0 0 0 0 1 0 0 0 0 0 0 0 0
capitalLeaseObligations 178M 184M 173M 167M 136M 165M 134M 139M 138M 139M 135M 142M 138M
totalLiabilities 2 187M 2 207M 2 027M 2 008M 2 185M 2 423M 2 490M 2 622M 2 781M 2 938M 1 745M 1 735M 1 842M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 762 000 761 000 758 000 588 000 588 000 588 000 588 000 588 000 588 000 588 000 586 000 586 000 583 000
retainedEarnings 6 342M 6 081M 5 225M 4 992M 4 770M 4 540M 4 402M 4 253M 4 088M 3 920M 3 760M 3 614M 3 080M
accumulatedOtherComprehensiveIncomeLoss -61M -75M -132M -252M -265M -208M -320M -273M -262M -270M -406M -313M -193M
othertotalStockholdersEquity -161M 101M 125M 150M 168M 106M 88M 79M
totalStockholdersEquity 6 121M 5 968M 5 195M 4 864M 4 630M 4 482M 4 250M 4 130M 3 933M 3 738M 3 433M 3 361M 2 886M
totalEquity 6 121M 5 968M 5 195M 4 864M 4 630M 4 482M 4 250M 4 130M 3 933M 3 738M 3 433M 3 361M 2 886M
totalLiabilitiesAndStockholdersEquity 8 308M 7 222M 6 815M 6 905M 6 741M 6 714M 6 676M 5 178M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 8 308M 8 174M 7 222M 6 872M 6 815M 6 905M 6 741M 6 752M 6 714M 6 676M 5 178M 5 096M 4 728M
totalInvestments 165M 85M -279M 170M 175M 160M -265M 157M 0 -346M 0 67M 75M
totalDebt 846M 852M 850M 874M 1 167M 1 391M 1 496M 1 580M 1 724M 1 939M 931M 918M 794M
netDebt -537M -358M 424M 636M 930M 1 181M 1 287M 1 352M 1 496M 1 686M 723M 644M 498M
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link
filingDate 2025-08-08 2024-08-09 2023-08-11 2022-08-12 2021-08-17
fiscalYear 2025 2024 2023 2022 2021
accountsReceivables 939M 837M 705M 576M 614M
otherReceivables 51M 0 0 0 0
prepaids 213M 280M 257M 207M 208M
totalPayables 446M 372M 247M 230M 473M
otherPayables 168M 135M 96M 71M 335M
accruedExpenses 364M 346M 332M 316M 294M
capitalLeaseObligationsCurrent 31M 25M 22M 22M 24M
capitalLeaseObligationsNonCurrent 153M 141M 117M 120M 115M
treasuryStock -2 073M -1 773M -1 623M -1 623M -1 623M
additionalPaidInCapital 2 034M 1 897M 1 772M 1 682M 1 622M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q2
date 2025-09-30 2025-06-30 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-06-30
symbol RMD RMD RMD RMD RMD RMD RMD RMD RMD RMD RMD RMD RMD
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 943 819 943 819 943 819 943 819 943 819 943 819 943 819 943 819 943 819 943 819 943 819 943 819 943 819
fillingDate 2025-10-31 2024-10-25 2024-04-26 2024-01-25 2023-10-27 2023-04-28 2023-01-27 2022-10-28
acceptedDate 2025-10-30 20:01:49 2025-08-07 20:44:48 2024-10-24 19:37:22 2024-08-08 20:09:34 2024-04-25 19:18:46 2024-01-24 19:50:30 2023-10-26 19:38:03 2023-08-10 20:15:16 2023-04-27 19:15:37 2023-01-26 18:09:53 2022-10-27 18:26:57 2022-08-11 21:09:45 2021-08-16 21:43:33
calendarYear 2026 2025 2024 2024 2024 2023 2023 2023
period Q1 FY Q1 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY FY
netIncome 349M 1 401M 311M 1 021M 300M 209M 219M 898M 233M 225M 210M 779M 475M
depreciationAndAmortization 58M 236M 54M 216M 55M 53M 53M 198M 53M 46M 44M 194M 192M
deferredIncomeTax 0 0 0 0 0 44M -33M 216 000 0 0 0 0 -3M
stockBasedCompensation 21M 92M 20M 80M 20M 20M 19M 71M 18M 16M 17M 65M 64M
changeInWorkingCapital 25M 17M -59M 45M 41M -44M -10M -462M -14M -153M -232M -708M 1M
accountsReceivables 30M -77M 36M -134M -56M -27M 7M -107M -13M -20M -56M 19M -129M
inventory -15M -80M -70M 172M 86M 50M 27M -249M -22M -86M -147M -312M -22M
accountsPayables 0 91M -25M 0 0 -44M 0 31M 0 0 8M -248M 211M
otherWorkingCapital 10M 83M -123 000 7M 11M -23M -33M -138M 20M -47M -37M -168M -58M
otherNonCashItems 5M 7M -283 000 39M 86M -9M 38M -11M -6M -6M 5M 21M 9M
netCashProvidedByOperatingActivities 457M 1 752M 326M 1 401M 402M 273M 286M 693M 283M 129M 45M 351M 737M
investmentsInPropertyPlantAndEquipment -43M -90M -18M -99M -23M -25M -41M -134M -31M -32M -32M -156M -117M
acquisitionsNet -522 000 -139M 0 -133M -3M -8M -103M -1 013M -13M -992M -19M -43M -39M
purchasesOfInvestments -2M -6M -1M -22M -2M -9M -5M -32M -13M -13M -7M -21M -22M
salesMaturitiesOfInvestments 0 0 23M 1 000 000 0 5M 250 000 4M 16M 10M 0 7M 0
otherInvestingActivites -7M -2M -5M -5M -2M 13M 0 0
netCashUsedForInvestingActivites -53M 2M -33M -41M -149M -28M -1 026M -59M
debtRepayment 0 -30M -220M -130M -185M -215M -15M -30M
commonStockIssued 8M 8M 5M 20M 983 000 983 000 22M 3M
commonStockRepurchased -150M -300M -50M -150M -50M -50M 105M 0 0 0 0 0 0
dividendsPaid -88M -78M -70M -71M -71M -65M -65M -64M
otherFinancingActivites -719 000 -1M -314 000 -8M -2M -900 000 990M 50M
netCashUsedProvidedByFinancingActivities -230M -151M -336M -239M -151M -280M 933M -42M
effectOfForexChangesOnCash -71 000 26M 11M -2M -5M 8M -5M -2M -208 000 11M -11M -14M 18M
netChangeInCash 174M 971M 188M 10M 28M 1M -19M -46M -25M 46M -67M -22M -168M
cashAtEndOfPeriod 1 384M 1 209M 426M 238M 238M 210M 209M 228M 228M 253M 207M 274M 295M
cashAtBeginningOfPeriod 1 209M 238M 238M 228M 210M 209M 228M 274M 253M 207M 274M 295M 463M
operatingCashFlow 457M 1 752M 326M 1 401M 402M 273M 286M 693M 283M 129M 45M 351M 737M
capitalExpenditure -43M -90M -20M -115M -23M -25M -41M -134M -31M -32M -32M -156M -117M
freeCashFlow 414M 1 662M 306M 1 286M 379M 248M 245M 559M 251M 97M 12M 195M 620M
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link
filingDate 2025-08-08 2024-08-09 2023-08-11 2022-08-12 2021-08-17
fiscalYear 2025 2024 2023 2022 2021
otherInvestingActivities 35M -15M 15M -17M 19M
netCashProvidedByInvestingActivities -200M -270M -1 160M -230M -158M
netDebtIssuance -40M -730M 665M 122M -522M
longTermNetDebtIssuance -40M -730M 665M 122M -522M
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance -226M -97M 49M 47M 38M
netCommonStockIssuance -226M -97M 49M 47M 38M
commonStockIssuance 74M 53M 49M 47M 38M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid -311M -282M -258M -245M -227M
commonDividendsPaid -311M -282M -258M -245M -227M
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities -30M -10M -33M -52M -54M
netCashProvidedByFinancingActivities -606M -1 119M 423M -128M -765M
incomeTaxesPaid 214M 278M 217M 478M 221M
interestPaid 28M 46M 47M 22M 24M

Earning call transcript

2025 q4
2026-01-29 ET (fiscal 2026 q2)
2025 q3
2025-10-30 ET (fiscal 2026 q1)
2025 q2
2025-07-31 ET (fiscal 2025 q4)
2025 q1
2025-04-23 ET (fiscal 2025 q3)
2024 q4
2025-01-30 ET (fiscal 2025 q2)
2024 q3
2024-10-24 ET (fiscal 2025 q1)
2024 q2
2024-08-01 ET (fiscal 2024 q4)
2024 q1
2024-04-25 ET (fiscal 2024 q3)
2023 q4
2024-01-24 ET (fiscal 2024 q2)
2023 q3
2023-10-26 ET (fiscal 2024 q1)
2023 q2
2023-08-03 ET (fiscal 2023 q4)
2023 q1
2023-04-27 ET (fiscal 2023 q3)
2022 q4
2023-01-26 ET (fiscal 2023 q2)
2022 q3
2022-10-27 ET (fiscal 2023 q1)
2022 q2
2022-08-11 ET (fiscal 2022 q4)
2022 q1
2022-04-28 ET (fiscal 2022 q3)
2021 q4
2022-01-27 ET (fiscal 2022 q2)
2021 q3
2021-10-28 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 8
2026-01-29 16:05 ET
ResMed reported for 2025 q4
SEC form 8
2026-01-29 16:05 ET
ResMed published news for 2025 q4
SEC form 8
2025-10-30 20:06 ET
ResMed reported for 2025 q3
SEC form 8
2025-10-30 20:06 ET
ResMed published news for 2025 q3
SEC form 8
2025-07-31 20:05 ET
ResMed reported for 2025 q2
SEC form 8
2025-07-31 20:05 ET
ResMed published news for 2025 q2
SEC form 10
2025-04-24 00:00 ET
ResMed published news for 2025 q1
SEC form 10
2025-04-23 22:20 ET
ResMed published news for 2025 q1
SEC form 8
2025-04-23 20:05 ET
ResMed reported for 2025 q1
SEC form 8
2025-04-23 20:05 ET
ResMed published news for 2025 q1
SEC form 10
2025-01-31 00:08 ET
ResMed published news for 2024 q4
SEC form 10
2025-01-31 00:00 ET
ResMed reported for 2024 q4
SEC form 8
2025-01-30 16:05 ET
ResMed published news for 2024 q4
SEC form 8
2025-01-30 16:05 ET
ResMed published news for 2024 q4
SEC form 10
2024-10-25 00:00 ET
ResMed reported for 2024 q3
SEC form 10
2024-10-24 19:37 ET
ResMed published news for 2024 q3
SEC form 8
2024-10-24 00:00 ET
ResMed published news for 2024 q3
SEC form 8
2024-10-24 00:00 ET
ResMed published news for 2024 q3
SEC form 10
2024-08-09 00:00 ET
ResMed published news for 2024 q2
SEC form 8
2024-08-01 16:05 ET
ResMed published news for 2024 q2
SEC form 8
2024-08-01 16:05 ET
ResMed reported for 2024 q2
SEC form 10
2024-04-26 00:00 ET
ResMed published news for 2024 q1
SEC form 10
2024-04-25 19:18 ET
ResMed published news for 2024 q1
SEC form 8
2024-04-25 16:07 ET
ResMed published news for 2024 q1
SEC form 8
2024-04-25 16:07 ET
ResMed reported for 2024 q1
SEC form 10
2024-01-25 00:00 ET
ResMed published news for 2023 q4
SEC form 10
2024-01-24 19:50 ET
ResMed published news for 2023 q4
SEC form 8
2024-01-24 16:06 ET
ResMed reported for 2023 q4
SEC form 8
2024-01-24 16:06 ET
ResMed published news for 2023 q4
SEC form 10
2023-10-27 00:00 ET
ResMed published news for 2023 q3
SEC form 10
2023-10-26 19:38 ET
ResMed published news for 2023 q3
SEC form 8
2023-10-26 16:05 ET
ResMed reported for 2023 q3
SEC form 10
2023-08-11 00:00 ET
ResMed published news for 2023 q2
SEC form 6
2023-08-03 16:06 ET
ResMed reported for 2023 q2
SEC form 8
2023-08-03 00:00 ET
ResMed published news for 2023 q2
SEC form 10
2023-04-28 00:00 ET
ResMed published news for 2023 q1
SEC form 8
2023-04-27 00:00 ET
ResMed published news for 2023 q1
SEC form 6
2023-03-30 16:36 ET
ResMed published news for 2022 q4
SEC form 10
2023-01-27 00:00 ET
ResMed reported for 2022 q4
SEC form 10
2023-01-26 18:09 ET
ResMed reported for 2022 q4
SEC form 6
2023-01-26 16:05 ET
ResMed published news for 2022 q4
SEC form 8
2023-01-26 00:00 ET
ResMed reported for 2022 q4
SEC form 6
2022-11-17 16:08 ET
ResMed published news for 2022 q3
SEC form 10
2022-10-28 00:00 ET
ResMed reported for 2022 q3
SEC form 10
2022-10-27 18:26 ET
ResMed reported for 2022 q3
SEC form 6
2022-10-27 16:05 ET
ResMed published news for 2022 q3
SEC form 8
2022-10-27 00:00 ET
ResMed reported for 2022 q3
SEC form 6
2022-10-05 14:02 ET
ResMed published news for 2022 q3
SEC form 10
2022-08-12 00:00 ET
ResMed reported for 2022 q2
SEC form 10
2022-08-11 21:09 ET
ResMed reported for 2022 q2
SEC form 6
2022-08-11 20:57 ET
ResMed published news for 2022 q2
SEC form 6
2022-08-11 16:07 ET
ResMed published news for 2022 q2
SEC form 8
2022-08-11 00:00 ET
ResMed reported for 2022 q2
SEC form 6
2022-07-01 13:03 ET
ResMed published news for 2022 q2
SEC form 6
2022-06-30 17:28 ET
ResMed published news for 2022 q1
SEC form 6
2022-06-14 09:07 ET
ResMed published news for 2022 q1
SEC form 6
2022-05-11 16:28 ET
ResMed published news for 2022 q1
SEC form 10
2022-04-29 00:00 ET
ResMed reported for 2022 q1
SEC form 10
2022-04-28 18:47 ET
ResMed reported for 2022 q1
SEC form 6
2022-04-28 16:07 ET
ResMed published news for 2022 q1
SEC form 8
2022-04-28 00:00 ET
ResMed reported for 2022 q1
SEC form 10
2022-01-28 00:00 ET
ResMed published news for 2021 q4
SEC form 10
2022-01-27 18:21 ET
ResMed published news for 2021 q4
SEC form 6
2022-01-27 16:06 ET
ResMed published news for 2021 q4
SEC form 8
2022-01-27 00:00 ET
ResMed published news for 2021 q4
SEC form 6
2021-11-19 14:31 ET
ResMed published news for 2021 q3
SEC form 10
2021-10-29 00:00 ET
ResMed published news for 2021 q3
SEC form 10
2021-10-28 18:28 ET
ResMed published news for 2021 q3
SEC form 6
2021-10-28 16:07 ET
ResMed published news for 2021 q3
SEC form 8
2021-10-28 00:00 ET
ResMed published news for 2021 q3
SEC form 6
2021-10-07 14:03 ET
ResMed published news for 2021 q3
SEC form 6
2021-10-06 12:08 ET
ResMed published news for 2021 q3
SEC form 6
2021-09-13 16:01 ET
ResMed published news for 2021 q2
SEC form 6
2021-08-27 16:06 ET
ResMed published news for 2021 q2
SEC form 6
2021-08-19 10:23 ET
ResMed published news for 2021 q2
SEC form 10
2021-08-17 00:00 ET
ResMed published news for 2021 q2
SEC form 10
2021-08-16 21:43 ET
ResMed published news for 2021 q2
SEC form 6
2021-08-05 16:08 ET
ResMed published news for 2021 q2
SEC form 8
2021-08-05 00:00 ET
ResMed published news for 2021 q2
SEC form 10
2021-04-30 00:00 ET
ResMed published news for 2021 q1
SEC form 10
2021-04-29 19:50 ET
ResMed published news for 2021 q1
SEC form 6
2021-04-29 16:06 ET
ResMed published news for 2021 q1
SEC form 8
2021-04-29 00:00 ET
ResMed published news for 2021 q1
SEC form 6
2021-03-29 17:54 ET
ResMed published news for 2020 q4
SEC form 10
2021-01-28 17:55 ET
ResMed published news for 2020 q4
SEC form 6
2021-01-28 16:05 ET
ResMed published news for 2020 q4
SEC form 6
2020-11-20 16:05 ET
ResMed published news for 2020 q3
SEC form 6
2020-11-05 16:08 ET
ResMed published news for 2020 q3
SEC form 10
2020-10-29 19:21 ET
ResMed published news for 2020 q3
SEC form 6
2020-10-29 16:05 ET
ResMed published news for 2020 q3
SEC form 6
2020-10-06 16:12 ET
ResMed published news for 2020 q3